-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our target price at $12 using a forward P/E of 6.0x our 2027 EPS view of $1.99, a discount to the five-year average on near-term fundamental concerns and lingering litigation issues. We keep our 2026 EPS view at $1.33 and our 2027 EPS at $1.99. We keep our Sell rating on shares of Chemours Company after Q1 earnings release as we think CC faces high risk from a multitude of litigation issues, most notably its involvement in PFAS lawsuits and may be negatively impacted by increased regulation on chemicals. CC posted net sales of $1.381B (+1% Y/Y) with mixed segment performances. Solid performance in the TSS segment (+22% Y/Y) fell short to counterbalance headwinds in the TT segment with sales declining 6% Y/Y and in the APM segment, with sales down 17% Y/Y. The Washington Works plant outage also constrained production in Q1, contributing ~$25M negative impact and highlights operational execution risks across the company's manufacturing footprint, in our view.